MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)

• Status: Completed
• Trial end date: 2008-02-21
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with Type 2 Diabetes Mellitus (T2DM) (a specific type of diabetes).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Metformin; Sitagliptin Phosphate

Criteria

Inclusion Criteria:

54-Week Base Study:

• Patients between the ages of 18 and 78 with Type 2 Diabetes Mellitus (a specific type of diabetes)

50-Week Extension Study:

• Patients who complete the 54-week base study are eligible to enter the 50-week extension study

Exclusion Criteria:

• Patients who do not have Type 2 Diabetes Mellitus (a specific type of diabetes)